Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded to "Buy" at Wall Street Zen

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday.

Separately, Hsbc Global Res raised shares of Bayer Aktiengesellschaft to a "hold" rating in a research note on Monday, April 28th.

Bayer Aktiengesellschaft Trading Up 4.3%

BAYRY opened at $7.52 on Friday. Bayer Aktiengesellschaft has a 1-year low of $4.79 and a 1-year high of $8.58. The stock has a market capitalization of $29.56 billion, a PE ratio of -28.93 and a beta of 0.84. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. The firm has a 50-day moving average price of $6.42 and a two-hundred day moving average price of $5.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.02. The business had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. As a group, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.